Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease

Blood

Volumn 89, Issue 4, 1997, Pages 1452-1459

  Chen, Yanfei ^a   Schlegel, Paul G ^a   Tran, Namphuong ^a   Thompson, Diana ^a   Zehnder, James L ^a   Chao, Nelson J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; MICROSATELLITE DNA; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DNA DETERMINATION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; INTRAPERITONEAL DRUG ADMINISTRATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031050303     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.4.1452     Document Type: Article

References (50)

1. Newman PJ, Berndt MC, Gorski J, White GC II, Lyman S, Paddock C, Muller WA: PECAM (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene supertamily. Science 247:1219, 1990
2. Simmons DL, Walker C, Power C, Pigott R: Molecular cloning ot CD31, a putative intercellular adhesion molecule closely related to carcinoembryonic antigen. J Exp Med 171:2147, 1990
3. Stockinger H, Gadd SJ, Eher R,. Majdic O, Schrieber W, Kasinrerk W, Strauss B, Schnabl E. Knapp W: Molecular characterization and functional analysis of the leukocyte surface protein CD31. J Immunol 145:3889, 1990
4. Zehnder JL, Hirai K, Shatsky M, McGregor J, Levin L, Leung L: The cell adhesion molecule CD31 is phosphorylated after cell activation. Down-regulation of CD31 in activated T lymphocytes. J Biol Chem 267:5243, 1992
5. Williams AF, Barclay AN: The immunoglobulin gene superfamily-domains for cell surface recognition. Annu Rev Immunol 6:381, 1988
6. Stockinger H, Schrieber W, Majdic O, Hoher W, Maurer D, Knapp W: Phenotype of human T cells expressing CD31, a molecule of the immunoglobulin supergene family. Immunology 75:53, 1992
7. Tanaka Y, Albelda SM, Horgan KJ, Van Seventer GA, Shimuzu Y, Newman PJ, Buck CA, Shaw S: CD31 expressed on distinctive T cell subsets is a preferential amplifier of β1 integrin-mediated adhesion. J Exp Med 176:245, 1992
8. Albelda SM, Muller WA, Buck CA, Newman PJ: Molecular and cellular properties of PECAM-I (endoCAM/ CD31): A novel vascular cell-cell adhesion molecule. J Cell Biol 114:1059, 1991
9. Muller WA, Berman ME, Newman PJ, DeLisser HM, Albelda SM: A heterophilic adhesion mechanism for platelet/endothelial cell adhesion molecule 1 (CD31). J Exp Med 175:1401, 1992
10. DeLisser HM, Yan H-C, Newman PJ, Muller WA, Buck CA, Albelda SM: Platelet/endothelial cell adhesion molecule-1 (CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans. J Biol Chem 268:16037, 1993
11. DeLisser HM, Chilkotowsky J, Yan H-C, Daise ML, Buck CA, Albelda SM: Deletions in the cytoplasmic domain of platelet-endothelial cell adhesion molecule-1 (PECAM-I, CD31) result in changes in ligand binding properties. J Cell Biol 124:195, 1994
12. Albelda SM, Oliver PD, Romer LH, Buck CA: EndoCAM: A novel endothelial cell-cell adhesion molecule. J Cell Biol 110:1227, 1990
13. Van Mourik JA, Leeksma OC, Reinders JH, de Groot PG, Zanbergen-Spaargaren J: Vascular endothelial cells synthesize a plasma membrane protein indistinguishable from the platelet membrane glycoprotein Ila. J Biol Chem 260:11300, 1985
14. Muller WA, Weigl SA, Deng X, Phillips DM: PECAM-I is required for transendothelial migration of leukocytes. J Exp Med 178:449, 1993
15. Vaporciyan AA, DeLisser HM, Yan H-C, Mediguren II, Thorn SR, Jones ML, Ward PA, Albelda SM: Involvement of platelet-endothelial adhesion molecule-1 in neutrophil recruitment in vivo. Science 262:1580, 1993
16. Zehnder JL, Shatsky M, Leung L, Butcher EC, McGregor JL, Levitt LJ: Involvement of CD31 in lymphocyte-mediated immune responses: Importance of the membrane-proximal immunoglobulin domain and identification of an inhibiting CD31 peptide. Blood 85:1282, 1995
17. Xie Y, Muller WA: Molecule cloning and adhesive properties of murine platelet/endothelial cell adhesion molecule-1 (PECAM-1). Proc Natl Acad Sci USA 90:5569, 1993
18. Bogen SA, Balbwin HS, Watkin SC, Albelda SM, Abbas AK: Association of murine CD31 with transmigrating lymphocytes following antigenic stimulation. Am J Pathol 14:843, 1992
19. Hamilton BL: L3T4-positive cells participate in the induction of graft-versus-host disease in response to minor histocompatibility antigens. J Immunol 139:2511, 1987
20. Piguet PF, Grau GE, Allet B, Vasalli P: Tumor necrosis factor is an effector of skin and gut lessions of the acute phase of graft-versus-host disease. J Exp Med 166:1820, 1987
21. Schlegel PG, Aharoni R, Smilek DE, Fernandez LP, McDevitt HO, Tran NP, Vaysburd M, Chao NJ: Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 84:2802, 1994
22. Jacob CO, Mykytyn K, Tashman N: DNA polymorphism in cytokine genes based on length variation in simple-sequence tandem repeats. Immunogenetics 38:251, 1993
23. Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ: Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol 155:3856, 1995
24. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw, Ledbetter JA, and Linsley PS. Induction of alloantigen-specitic hyporesponsiveness in human T lymphocytes by blocking interation of CD28 with natural ligand B7/BB1. J Exp Med 177:165, 1993
25. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W: Current Protocol in Immunology: Proliferative Assays for T Cell Function, vol 1. New York, NY, Wiley, 1994, p 3.12.1
26. Zamvil S, Nelson P, Trotter J, Mitchell D, Knobler R, Fritz R, Steinman L: T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317:355, 1985
27. Wraith DC, Smilek DE, Mitchell DE, Steinman L, McDevitt HO: Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 59:247, 1989
28. Chao NJ: Graft-versus-host disease following allogeneic bone marrow transplantation. Curr Opin Immunol 4:571, 1992
29. Roopenian DC, Christianson GJ, Davis AP, Zuberi AR, Mobraaten LE: The genetic origin of minor histocompatibility antigens. Immunogenetics 38:131, 1993
30. Wallny PJ, Rammensee HG: Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343:275, 1990
31. Vallera DA, Ash RC, Zanjani ED, Kersey JH, Lebien TW, Beverley PCL, Neville DM Jr, Youle RJ: Anti-T cell reagents for human bone marrow transplantation: Ricin linked to three monoclonal antibodies. Science 22:512, 1983
32. Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-IG reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83:3815, 1994
33. Lanzavecchia A: Identifying strategies for immune intervention. Science 260:937, 1993
34. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349, 1990
35. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
36. Rothbard JB, Gefter ML: Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 9:527, 1991
37. Kawakami K, Yamamoto Y, Kakimoto K, Onoue K: Requirement for delivery of signals by physical interactions and soluble factors from accessory cells in the induction of receptor-mediated T cell proliferation: Effectiveness of IFN gamma modulation of accessory cells for physical interaction with T cells. J Immunol 142:1818, 1989
38. + T cells. J Exp Med 179:1539, 1994
39. Otten GR, Germain RN: Split anergy in a CD8 T cell: Receptor-dependent cytolysis in the absence of interleukin-2 production. Nature 251:1228, 1991
40. Hardning FA, McArthur JG, Gross GA, Raulet DH, Allison JP: CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 356:607, 1992
41. Mueller DL, Jenkins MK, Schwartz RH: Clonal expension versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell receptor antigen occupancy. Annu Rev Immunol 7:445, 1989
42. + T lymphocytes. J Immunol 148:1985, 1992
43. Damle NK, Klussman K, Linsley PS, Aruffo A, Ledbetter: Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7. J Immunol 149:2541, 1992
44. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA: Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85:2607, 1995
45. 3 integrin involved in adhesion of leukocyte to endotheiium. J Cell Biol 130:451, 1995
46. Staunton DE, Dustin ML, Erickson HP, Springer TA: The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinorivus. Cell 61:243, 1990
47. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyl S, Hemler M, Lobb R: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577, 1990
48. + hematopoietic precursor cells with early myeloid and B-lymphoid cell phenotypes. Blood 82:2649, 1993
49. Williams AF, Barclay AN: The immunoglobulin superfamily-Domains for eell surface recognition. Annu Rev Immunol 6:381, 1988
50. Prager E, Plassmann RS, Hansmann C, Koch C, Holter W, Knapp W, Stockinger H: Interaction of CD31 with a heterophilic counterreceptor involved in downregulation of human T cell responses. J Exp Med 184:41, 1996